Silo Pharma, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring between February 20, 2026, and February 23, 2026, for Silo Pharma, Inc., a Nevada corporation listed on The Nasdaq Stock Market under the symbol "SILO."
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses on specific corporate actions involving equity and cash commitments.
- Commitment Fee: $250,000 paid to an investor relations consultant.
- Stock Issuance: 848,320 shares of Common Stock issued to settle the commitment fee.
- Valuation Basis: Shares calculated at $0.2947 per share (Nasdaq Minimum Price).
- Proceeds: No cash proceeds were received by the Company for this issuance.
- Repurchase Authorization: Up to $1,000,000 authorized for stock buybacks.
Material Changes
The filing details two material events:
- Unregistered Sale of Equity (Item 3.02): On February 20, 2026, the Company entered into an addendum to a Service Agreement with its investor relations consultant. The consultant received 848,320 shares of Common Stock in lieu of a $250,000 cash commitment fee. This issuance was made pursuant to Section 4(a)(2) of the Securities Act of 1933.
- Stock Repurchase Program (Item 8.01): On February 23, 2026, the Board of Directors approved a program to repurchase up to $1 million of the Company's common stock.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors beyond the standard disclosures associated with unregistered securities sales and stock repurchases. The issuance of shares for services represents a dilution event for existing shareholders.
Investor Verification Checklist
- Verify the impact of the 848,320 share issuance on total outstanding shares and earnings per share.
- Confirm the terms and execution timeline of the $1 million stock repurchase program.
- Review the attached press release (Exhibit 99.1) for additional details on the repurchase strategy.
- Check subsequent filings for the actual volume and price of shares repurchased under the new program.